Resapp Health (RAP.AX) Aandeel Koers
Resapp Health Koers
De omzet is de afgelopen 16 jaar met 19,7% per jaar gegroeid tot 2,51 Miljoen AUD. De nettowinstmarge van Resapp Health ligt op -282,5% en is ten opzichte van -238.247,0% enkele jaren eerder gestegen.
Resapp Health aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Resapp Health bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Resapp Health
Resapp Health Ltd is a medical technology company that specializes in the development of innovative respiratory diagnostic and management solutions. Their business model revolves around designing and commercializing smartphone-based applications, algorithms, and software solutions for the diagnosis and management of respiratory conditions. By utilizing the power of artificial intelligence and machine learning, Resapp Health Ltd aims to provide accurate, accessible, and cost-effective respiratory healthcare to patients worldwide. With a focus on improving respiratory disease outcomes, their technologies have the potential to revolutionize the way respiratory conditions are diagnosed and managed, ultimately leading to better patient outcomes and reduced healthcare costs.
Resapp Health Ltd is primarily active in the healthcare industry.
The main competitors of Resapp Health Ltd in the market include companies such as ResMed Inc., Fisher & Paykel Healthcare Corporation Limited, and Masimo Corporation.
Resapp Health Ltd, an innovative healthcare company, has a notable history and background. Founded in 2014, Resapp is dedicated to developing digital healthcare solutions centered around respiratory diseases. The company focuses on creating intelligent software that can diagnose and manage respiratory conditions using cough sounds and patient data. Resapp Health Ltd operates in the global market and has expanded its reach by collaborating with renowned medical institutions and research centers. With its cutting-edge technology and a team of experienced professionals, Resapp Health Ltd strives to improve the healthcare landscape and provide effective solutions for respiratory health.
Resapp Health Ltd has achieved a number of significant milestones. They successfully developed and launched ResAppDx, a smartphone-based diagnostic test for respiratory diseases. The company also received regulatory clearance in both the United States and European Union for their products. Resapp Health Ltd has entered into partnerships with leading healthcare institutions and companies to advance their technology and expand their market reach. They have conducted several successful clinical studies validating the accuracy and effectiveness of their diagnostic platform. Resapp Health Ltd's continuous innovation and commitment to improving respiratory healthcare positions them as a leader in the field.
Resapp Health Ltd is primarily present in Australia and the United States.
Resapp Health Ltd is a leading digital health company that focuses on developing innovative solutions to improve respiratory diagnostics and management. The company's values revolve around delivering accurate, accessible, and cost-effective healthcare solutions. Resapp Health is committed to leveraging cutting-edge technology and research to positively impact patient outcomes and healthcare efficiency. With a customer-centric approach, the company prioritizes collaboration, transparency, and integrity in all its endeavors. By constantly pushing the boundaries of respiratory healthcare, Resapp Health aims to revolutionize the industry and make a meaningful difference in the lives of individuals worldwide.
5 analisten beoordelen het aandeel Resapp Health momenteel: 4 adviseren kopen, 1 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Resapp Health op 0,01 EUR (0,02 AUD).
ResApp Health Ltd is an Australian company that develops innovative digital health solutions based on artificial intelligence. The company's business model is to optimize healthcare in various areas by offering its proprietary technologies and products. ResApp Health's main areas of focus are the diagnosis and treatment of respiratory diseases, particularly in children. The company has developed a patented technology that analyzes cough sounds to support the diagnosis of conditions such as asthma, bronchitis, or pneumonia. This technology is available in the form of a mobile app that allows parents and caregivers to record cough sounds and receive a diagnosis within minutes. ResApp Health has also developed products and technologies to support healthcare professionals in the diagnosis of respiratory diseases. The company has developed a portable device called "Smarthaler" that monitors patients' airways and captures measurements such as respiratory rate and volume. These data are transmitted in real-time to an app that helps doctors and nurses detect conditions early and respond to changes more quickly. Another division of ResApp Health is telemedicine. The company has developed a platform that allows patients and doctors to communicate from anywhere. This platform offers various telemedicine services such as video consultations, electronic prescriptions, or digital medical records. This allows patients, especially those in rural areas or with limited mobility, to benefit from better healthcare. ResApp Health works closely with medical institutions and research facilities to improve and develop its technologies and products. The company has partnerships with renowned research institutions such as the University of Queensland or the Cleveland Clinic to conduct clinical studies and validate its technologies. The business model of ResApp Health is based on a mixture of products and services that improve healthcare in an innovative and intuitive way. The patented technology for the diagnosis of respiratory diseases enables rapid and accurate diagnosis, while the portable device and telemedicine platform make healthcare more efficient and accessible. ResApp Health has a wide range of application areas such as pediatrics, geriatrics, or general medicine, making it a promising company in the field of digital health.
De omzet kan momenteel niet worden berekend voor Resapp Health.
De winst kan momenteel niet worden berekend voor Resapp Health.
De P/E-ratio kan momenteel niet worden berekend voor Resapp Health.
De P/S-ratio kan momenteel niet worden berekend voor Resapp Health.
De Eulerpool Kwaliteitsscore voor Resapp Health is 2/10.
De ISIN van Resapp Health is AU000000RAP5. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
Het tickersymbool van Resapp Health is RAP.AX. Onder dit beurstickersymbool wordt het Resapp Health-aandeel op de beurs verhandeld.
Resapp Health aandeel
Resapp Health Peer Group
Resapp Health FIGI
Alle fundamentals en diepgaande analyse van Resapp Health
Onze aandelenanalyse van het Resapp Health-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Resapp Health. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: